Free tool
FAERS Monitor: Vigafyde
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 217684 or its brand name (Vigafyde, Vigabatrin). Reports on generic versions are filed under their own applications.
Reports
4,764
Serious
3,805
80% of reports
Hospitalization
1,774
Death reported
453
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- seizure938
- drug ineffective709
- off label use372
- hospitalisation315
- death253
- adverse event247
- somnolence197
- epilepsy191
- multiple-drug resistance178
- magnetic resonance imaging head abnormal167
- drug resistance162
- vomiting161
- product use issue152
- status epilepticus152
- condition aggravated151
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 8 |
| 2005 | 15 |
| 2006 | 17 |
| 2007 | 10 |
| 2008 | 50 |
| 2009 | 27 |
| 2010 | 19 |
| 2011 | 22 |
| 2012 | 27 |
| 2013 | 56 |
| 2014 | 46 |
| 2015 | 46 |
| 2016 | 51 |
| 2017 | 72 |
| 2018 | 236 |
| 2019 | 309 |
| 2020 | 399 |
| 2021 | 439 |
| 2022 | 540 |
| 2023 | 581 |
| 2024 | 685 |
| 2025 | 665 |
| 2026 | 444 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,049,395 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| magnetic resonance imaging head abnormalSignal | 167 | 1530.9 | 1286.8 | 188,493 |
| multiple-drug resistanceSignal | 178 | 268.8 | 231.7 | 44,520 |
| status epilepticusSignal | 152 | 60.2 | 51.5 | 8,681 |
| seizureSignal | 938 | 36.1 | 34.1 | 31,928 |
| drug resistanceSignal | 162 | 28.0 | 24.1 | 4,172 |
| epilepsySignal | 191 | 27.7 | 24.1 | 4,875 |
| adverse eventSignal | 247 | 11.9 | 10.5 | 2,450 |
| hospitalisationSignal | 315 | 9.1 | 8.1 | 2,265 |
| somnolenceSignal | 197 | 4.3 | 3.8 | 504 |
| product use issueSignal | 152 | 3.6 | 3.1 | 281 |
| drug ineffectiveSignal | 709 | 2.4 | 2.2 | 601 |
| condition aggravatedSignal | 151 | 2.2 | 1.9 | 98 |
| off label use | 372 | 1.9 | 1.7 | 158 |
| vomiting | 161 | 1.5 | 1.3 | 28 |
| death | 253 | 1.3 | 1.2 | 18 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.